Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

TABATABAEI MALAZY OZRA; NORANI Masumeh; HESHMAT RAMIN; QORBANI MOSTAFA; VOSOOGH Afsaneh; AFRASHTEH Behnaz; KAHKESHAN Farzin; AJAMI Arman; LARIJANI BAGHER

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Public Health Year:2018 | Volume:47 | Issue:9 Page(s): 1335-1343

Download Full-Text

View:

250

Download:

182

Cites:

Information Journal Paper

Title

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

Author(s)

Keywords

Teriparatide

CinnoPar®

Postmenopausal osteoporosis

Clinical trial

Abstract

Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of frac-tures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant hu-man parathyroid hormone (CinnoPar® , CinnaGen, Iran) to the reference product (Forteo® , Eli Lilly, USA) in a randomized double-blind Clinical trial (RCT). Methods: Overall, 104 osteoporotic postmenopausal women aged 45-75 yr were randomized to receive 20 μ g daily subcutaneous injections of either Forteo® or CinnoPar® for 6-months from 2011-2012. Bone bi-omarkers were measured at baseline, and during first, third, and sixth month's follow-up along with lumbar spine, total hip, and femoral neck bone mineral density (BMD) assessment at the baseline and six months after that. The study was registered in Iranian registry of Clinical trials under the registration number of IRCT138810121414N5. The endpoints were to compare bone biomarkers, BMD and drug safety between groups. Data analysis was performed using SPSS 11. Results: Age range of ninety-four patients who completed the study was 42-81 yr. Participants were divided into Forteo (45 subjects) and CinnoPar (49 subjects) groups. No significant difference in terms of bone bi-omarkers or BMD scores was shown between groups (P≥ 0. 05). The most prevalent side effects were hyper-calcemia and hypercalciuria without any significant statistical differences between groups. Conclusion: CinnoPar® can be considered as a good alternative therapy for Forteo® in postmenopausal os-teoporotic women due to its comparable efficacy and safety properties.

Cites

No record.

References

No record.

Cite

APA: Copy

TABATABAEI MALAZY, OZRA, NORANI, Masumeh, HESHMAT, RAMIN, QORBANI, MOSTAFA, VOSOOGH, Afsaneh, AFRASHTEH, Behnaz, KAHKESHAN, Farzin, AJAMI, Arman, & LARIJANI, BAGHER. (2018). Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial. IRANIAN JOURNAL OF PUBLIC HEALTH, 47(9), 1335-1343. SID. https://sid.ir/paper/274900/en

Vancouver: Copy

TABATABAEI MALAZY OZRA, NORANI Masumeh, HESHMAT RAMIN, QORBANI MOSTAFA, VOSOOGH Afsaneh, AFRASHTEH Behnaz, KAHKESHAN Farzin, AJAMI Arman, LARIJANI BAGHER. Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial. IRANIAN JOURNAL OF PUBLIC HEALTH[Internet]. 2018;47(9):1335-1343. Available from: https://sid.ir/paper/274900/en

IEEE: Copy

OZRA TABATABAEI MALAZY, Masumeh NORANI, RAMIN HESHMAT, MOSTAFA QORBANI, Afsaneh VOSOOGH, Behnaz AFRASHTEH, Farzin KAHKESHAN, Arman AJAMI, and BAGHER LARIJANI, “Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial,” IRANIAN JOURNAL OF PUBLIC HEALTH, vol. 47, no. 9, pp. 1335–1343, 2018, [Online]. Available: https://sid.ir/paper/274900/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops